J. M. Ellis

发表

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Lynn A. Hyde, Z. Yin, M. Kennedy, 2015, The Journal of Pharmacology and Experimental Therapeutics.

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Matthew L. Maddess, A. Stepan, T. Sherer, 2020, Science Translational Medicine.

Current approaches to the treatment of Parkinson's Disease.

Matthew J. Fell, J. M. Ellis, M. Fell, 2017, Bioorganic & medicinal chemistry letters.

Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Karin M. Otte, G. Morriello, B. Pio, 2021, RSC medicinal chemistry.

Characterization of the onset, progression, and reversibility of morphological changes in mouse lung following pharmacological inhibition of LRRK2 kinase activity

Matthew L. Maddess, Karin M. Otte, M. Kennedy, 2021 .

A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system

D. Zaller, M. Crackower, H. Houshyar, 2017, PloS one.

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING.

M. Altman, H. Hatch, B. Pan, 2018, ACS medicinal chemistry letters.

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease.

Theodore A. Martinot, Michael J. Ardolino, Matthew L. Maddess, 2022, Journal of medicinal chemistry.

Strategy for Extending Half-life in Drug Design and Its Significance.

M. Altman, B. Lahue, Scott A. Johnson, 2018, ACS medicinal chemistry letters.

Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity

Matthew L. Maddess, Karin M. Otte, M. Kennedy, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.

M. Crackower, H. Houshyar, Hongshi Yu, 2013, American journal of respiratory cell and molecular biology.

Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.

Andrew M Haidle, Matthew L. Maddess, Youwei Yan, 2016, ACS medicinal chemistry letters.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Matthew L. Maddess, H. Houshyar, M. Altman, 2015, Journal of medicinal chemistry.

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

L. Hamann, J. Ellis, P. Chamberlain, 2019, ACS medicinal chemistry letters.